An example of a prostate cancer patient subpopulation that lacks a strong PSMA PET/CT tracer uptake includes men with neuroendocrine histology, for which PSMA-targeted imaging was described as being ineffectual [18]. This evidence concerns the gene FOLH1 and prostate cancer.